Chemical imaging brings cancer tissue analysis into the digital age
1/10/2014
A new method for analysing biological samples based on their chemical makeup is set to transform the way medical scientists examine diseased tissue.When tests are carried out on a patient's tissue today, such as to look for cancer, the test has to be interpreted by a histology specialist, and can take weeks to obtain a full result.
Inhibiting the growth of cancer cells using nano-capsules
1/10/2014
Researchers at the Winship Cancer Institute of Emory University have discovered a more effective drug delivery system using nanotechnology that could one day significantly affect cancer prevention.
Shield Therapeutics (Shield), an independent specialty pharmaceutical company focusedon the development of mineral-derived hospital pharmaceuticals, has announced stronglypositive top-line data from the pivotal Phase 3 programme of ST10 for the treatment ofiron deficiency anaemia (IDA) in inflammatory bowel disease (IBD).
Inhibiting the growth of cancer cells using nano-capsules
1/10/2014
Researchers at the Winship Cancer Institute of Emory University have discovered a more effective drug delivery system using nanotechnology that could one day significantly affect cancer prevention.
Chemical imaging brings cancer tissue analysis into the digital age
1/10/2014
A new method for analysing biological samples based on their chemical makeup is set to transform the way medical scientists examine diseased tissue.When tests are carried out on a patient's tissue today, such as to look for cancer, the test has to be interpreted by a histology specialist, and can take weeks to obtain a full result.
African American men at increased risk of prostate cancer
1/10/2014
African American men have an increased risk of prostate cancer and are two times more likely than Caucasian American men to die from the disease. Despite recent questions about the overall usefulness of prostate-specific antigen (PSA) testing to detect prostate cancer, should PSA screening be used to detect early-stage disease to help save lives in this at-risk population?
Dabrafenib in melanoma: added benefit not proven
1/10/2014
No differences could be shown for mortality, symptoms and quality of life / concerning side effects, data too uncertainDabrafenib (trade name: Tafinlar) has been approved in Germany since August 2013 for the treatment of advanced melanoma.
The epigenetics of breast cancer family history
1/10/2014
Breast cancer runs in families; however, genetic predisposition (such as being BRCA1 or BRCA2 mutation carriers) explains only a portion of this observation. Epigenetic changes (modifications in the genome that alter gene expression but do not affect the DNA sequence per se) have been shown to also play a role in breast cancer risk.
White women more prone to breast cancer because of lifestyle
1/09/2014
In England, black and South Asian women have lower rates of breast cancer than white women. Now, a new study from Oxford University suggests the reason lies with differences in lifestyle and reproductive patterns.The team, from Oxford's Cancer Epidemiology Unit, lists alcohol consumption, breastfeeding and number of children as some of the factors.
Molecular, protein targeting therapies may be best treatment for certain lung cancer
1/09/2014
University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition.